Information Provided By:
Fly News Breaks for June 30, 2017
ABMD
Jun 30, 2017 | 11:12 EDT
Piper Jaffray analyst Matt O'Brien encourages investors to start or build positions in Abiomed after the company announced the publication of a peer-reviewed study on the use of the Impella 2.5. The results are "quite strong" and add to the totality of the data on the use of the device in most high-risk percutaneous coronary intervention patients, O'Brien tells investors in a research note. The analyst views today's announcement as further evidence of the clinical benefits of Impella. He keeps an Overweight rating on Abiomed.
News For ABMD From the Last 2 Days
There are no results for your query ABMD